| 135 |
Strategy of Anti-Platelet Therapy After PCI in High-Risk Patients |
Youngwoo Jang |
Apr. 17. 25 |
| 134 |
Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease |
Do-Yoon Kang |
Apr. 17. 25 |
| 133 |
Strategic Long-Term Use of Clopidogrel in Acute Coronary Syndrome |
Si-Hyuck Kang |
Apr. 17. 25 |
| 132 |
Strategic Acute Phase ACS Management: Clopidogrel-Centric Approaches |
Sanghoon Shin |
Apr. 17. 25 |
| 131 |
How Do We Achieve Lower for Longer LDL-C Levels for Patients |
Ji-Wung Ryu |
Apr. 17. 25 |
| 130 |
What are the Real-World Issue to Keep LDL-C Lower for Longer |
Dong-Bin Kim |
Apr. 17. 25 |
| 129 |
Personalized LDL-C Reduction: Maximizing Outcomes With Alirocumab 300mg |
Eunkyu Lee |
Apr. 17. 25 |
| 128 |
LDL-C Lowering: Why Earlier is Better & When to Act? |
Choongki Kim |
Apr. 17. 25 |
| 127 |
The Lower the Better : Rosuvastatin’s Next Option for Dyslipidemia Management |
Doyeon Hwang |
Apr. 17. 25 |
| 126 |
True Atherosclerosis Regression With a 20-Year Legacy, Rosuvastatin |
Jeehoon Kang |
Apr. 17. 25 |
